Santhera Pharmaceuticals Holding AG Logo

Santhera Pharmaceuticals Holding AG

Develops innovative medicines for rare neuromuscular and mitochondrial disorders.

SANN | SW

Overview

Corporate Details

ISIN(s):
CH1276028821
LEI:
54930035HAOFTTQH0U85
Country:
Switzerland
Address:
HOHENRAINSTRASSE 24, 4133 PRATTELN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of innovative medicines for patients with rare diseases. The company targets conditions with high unmet medical needs, primarily in the area of rare neuromuscular and mitochondrial disorders. Santhera's mission is to provide treatment options for diseases that severely impact the lives of affected children and adults and currently have limited or no available therapies. Its development efforts include advanced treatments such as gene therapy for conditions like LAMA2-deficient congenital muscular dystrophy (CMD).

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Santhera Pharmaceuticals Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Santhera Pharmaceuticals Holding AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Santhera Pharmaceuticals Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-01-11 N/A Non-Executive member Buy None 42,600.00 CHF
2022-01-10 N/A Executive member Buy None 14,420.00 CHF
2022-01-05 N/A Executive member Buy None 37,000.00 CHF

Peer Companies

SunBio, Inc. Logo
Develops biopharmaceuticals and devices like artificial blood using proprietary PEGylation technology.
South Korea
067370
Sunshine Biopharma Inc. Logo
Develops novel oncology/antiviral drugs and commercializes generic pharmaceuticals in Canada.
United States of America
SBFM
SUPERNUS PHARMACEUTICALS, INC. Logo
Develops and commercializes therapies for CNS diseases like epilepsy, migraine, and ADHD.
United States of America
SUPN
SURMODICS INC Logo
Provides medical device coatings, vascular products, and components for diagnostic tests.
United States of America
SRDX
SUTRO BIOPHARMA, INC. Logo
Develops engineered cancer drugs like ADCs using a cell-free protein synthesis platform.
United States of America
STRO
Swedencare AB (publ) Logo
Develops and markets premium health supplements and pharmaceuticals for cats, dogs, and horses.
Sweden
SECARE
Swedish Orphan Biovitrum Logo
Develops innovative therapies for rare diseases in haematology, immunology, and specialty care.
Sweden
SOBI
SymBio Pharmaceuticals Limited Logo
Acquires and commercializes specialty drugs for unmet needs in Japan and the Asia-Pacific region.
Japan
4582
SynAct Pharma Logo
Biotech developing oral therapies to resolve inflammation in diseases like rheumatoid arthritis.
Sweden
SYNACT
SYNAIRGEN PLC Logo
Developing inhaled interferon beta treatments for severe viral lung infections in hospitalized patients.
United Kingdom
SNG

Talk to a Data Expert

Have a question? We'll get back to you promptly.